Phenylboronic ester-modified anionic micelles for ROS-stimuli response in HeLa cell

Area of Science:

• Biomaterials Science
• Nanotechnology
• Polymer Chemistry

Background:

• Smart polymers are promising drug nanocarriers due to stimuli-responsive drug release and reduced cytotoxicity.
• Intracellular stimuli, such as reactive oxygen species (ROS), are key triggers for targeted drug delivery.
• Developing efficient and safe nanocarriers is crucial for improving cancer chemotherapy efficacy.

Purpose of the Study:

• To develop and characterize a novel anionic micelle nanocarrier based on a phenylboronic ester (PBE) grafted copolymer (PEG-b-PAsp-g-PBE).
• To evaluate the stimuli-responsive drug release and anti-tumor activity of the PEG-b-PAsp-g-PBE/doxorubicin (DOX) system.
• To assess the in vivo efficacy and systemic toxicity of the developed nanocarrier compared to free DOX.

Main Methods:

• Synthesis and characterization of the PEG-b-PAsp copolymer and its subsequent grafting with PBE.
• Formation of anionic micelles and loading with doxorubicin (DOX).
• In vitro studies on HeLa cell lines to assess ROS-responsive drug release and cytotoxicity.
• In vivo studies on subcutaneous tumor models to evaluate tumor growth inhibition and systemic toxicity.

Main Results:

• The PEG-b-PAsp-g-PBE copolymer formed stable anionic micelles capable of encapsulating DOX.
• The nanocarrier demonstrated fast response to intracellular ROS, leading to enhanced drug release.
• PEG-b-PAsp-g-PBE/DOX exhibited superior tumor growth inhibition in HeLa cell lines and subcutaneous tumor models.
• Significantly lower systemic toxicity was observed for PEG-b-PAsp-g-PBE/DOX compared to free DOX.

Conclusions:

• PEG-b-PAsp-g-PBE serves as a highly efficient and safe nanocarrier for chemotherapy.
• The ROS-responsive nature of the nanocarrier enhances anti-tumor efficacy.
• This smart polymer nanocarrier holds significant potential for improving cancer treatment outcomes.